1. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines.
- Author
-
Hamm, Sebastian Rask, Loft, Josefine Amalie, Pérez-Alós, Laura, Heftdal, Line Dam, Hansen, Cecilie Bo, Møller, Dina Leth, Pries-Heje, Mia Marie, Hasselbalch, Rasmus Bo, Fogh, Kamille, Hald, Annemette, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Perch, Michael, Sørensen, Søren Schwartz, and Rasmussen, Allan
- Subjects
BOOSTER vaccines ,HUMORAL immunity ,TRANSPLANTATION of organs, tissues, etc. ,COVID-19 vaccines ,VACCINATION - Abstract
As solid organ transplant (SOT) recipients remain at risk of severe outcomes after SARS-CoV-2 infections, vaccination continues to be an important preventive measure. In SOT recipients previously vaccinated with at least three doses of BNT162b2, we investigated humoral responses to BNT162b2 booster doses. Anti-SARS-CoV-2 receptor binding domain (RBD) immunoglobulin G (IgG) was measured using an in-house ELISA. Linear mixed models were fitted to investigate the change in the geometric mean concentration (GMC) of anti-SARS-CoV-2 RBD IgG after vaccination in participants with intervals of more or less than six months between the last two doses of vaccine. We included 107 SOT recipients vaccinated with a BNT162b2 vaccine. In participants with an interval of more than six months between the last two vaccine doses, we found a 1.34-fold change in GMC per month (95% CI 1.25–1.44), while we found a 1.09-fold change in GMC per month (95% CI 0.89–1.34) in participants with an interval of less than six months between the last two vaccine doses, resulting in a rate ratio of 0.82 (95% CI 0.66 to 1.01, p = 0.063). In conclusion, the administration of identical COVID-19 mRNA vaccine boosters within six months to SOT recipients may result in limited humoral immunogenicity of the last dose. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF